Compare Palo Alto Networks Inc (PANW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Viatris Inc — how do they compare? Palo Alto Networks Inc trades at $418.78 (market cap $331.76B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Palo Alto Networks Inc is far larger — about 16.6× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Viatris Inc for 57 Days on average.
| PANW | VTRS | |
|---|---|---|
Market Cap | $331.76B | $20.03B |
Volume | 3,886,927 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $419.91 | $18.27 |
52-Week Low | $141.67 | $9.74 |
Typical Hold Time | 82 Days | 57 Days |
Enterprise Value | $331.19B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $418.78, up 3.3% with strong technical momentum near 52-week highs. The stock shows bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth remains robust at $9.22B for 2025, though valuation metrics appear elevated with P/E at 1,013.93 and P/S at 26.99. The company's platformization strategy and AI security services are driving investor optimism.
Outlook remains positive with 72% analyst buy ratings and $398.70 consensus target, though premium valuation and rising costs present risks. AI cybersecurity demand creates growth opportunities, but execution on large customer deals and margin sustainability will be critical for continued upside.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
